8-K filed October 10, 2023, 7:59 PM ET ticker ZVRA CIK 0001434647

leadership confidence high sentiment neutral materiality 0.60

Zevra Therapeutics appoints Neil F. McFarlane as CEO effective Oct 10, 2023

ZEVRA THERAPEUTICS, INC.

Neil F. McFarlane named President and CEO, succeeding interim CEO Christal Mickle who remains Chief Development Officer.
McFarlane receives $700k base salary, 60% target bonus, 600k stock options, and 200k RSUs vesting over 4 years.
Relocation assistance of $350k provided; severance includes 1x salary (1.5x upon change in control).
Board member Joseph B. Saluri resigned effective immediately after McFarlane's appointment.
McFarlane brings 25+ years biopharma experience, most recently CEO of Adamas Pharmaceuticals.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Joseph B. Saluri

Board member

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-10-10
Filed: October 10, 2023, 7:59 PM ET

Resignation of Joseph B. Saluri from B

Appointed

Neil F. McFarlane

President and Chief Executive Officer

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-10-10
Filed: October 10, 2023, 7:59 PM ET

appointed Neil F. McFarlane to serve as the Company’s President and Chief Executive Officer, effective October 10, 2023

Appointed

Neil F. McFarlane

member of the Board

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-10-10
Filed: October 10, 2023, 7:59 PM ET

Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board.

Role change

Christal M.M. Mickle

Chief Development Officer

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2023-10-10
Successor: Neil F. McFarlane
Filed: October 10, 2023, 7:59 PM ET

succeeding Christal M.M. Mickle., the Company’s former interim President and Chief Executive Officer, in such role. Ms. Mickle will continue serving in her role as Chief Development Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.8

Joseph B. Saluri resigned as Board member at ZEVRA THERAPEUTICS, INC..

Action: resigned
Role: Board member

Exact text from the filing

Resignation of Joseph B. Saluri from B

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil F. McFarlane was appointed as President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

appointed Neil F. McFarlane to serve as the Company’s President and Chief Executive Officer, effective October 10, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Neil F. McFarlane was appointed as member of the Board at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: member of the Board

Exact text from the filing

Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christal M.M. Mickle changed role as Chief Development Officer at ZEVRA THERAPEUTICS, INC..

Action: stepped down as interim President and Chief Executive Officer, continues as Chief Development Officer
Role: Chief Development Officer

Exact text from the filing

succeeding Christal M.M. Mickle., the Company’s former interim President and Chief Executive Officer, in such role. Ms. Mickle will continue serving in her role as Chief Development Officer.

View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-027993

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.